Legend Biotech Nears a Crucial Profitability Milestone

Following a robust performance in fiscal 2025, Legend Biotech Corp is on the cusp of reaching profitability. Company leadership projects that the business will achieve consolidated profitability as early as fiscal 2026. This anticipated shift is prompting a strategic realignment, moving the emphasis from pure research and development toward the efficient scaling of commercial operations.

Financial Health and Scaling Ambitions

The company enters this pivotal phase from a position of financial strength, holding cash and equivalents totaling $949 million. Management views this war chest as essential preparation for an increasingly competitive market landscape. The immediate focus for the coming quarters is squarely on managing costs during the global rollout and scaling of its CAR-T platform technology. Maintaining its recently achieved high manufacturing efficiency will be a key challenge as eligible patient numbers grow worldwide.

Carvykti: The Engine of Growth

The cornerstone of Legend Biotech’s success is its CAR-T cell therapy, Carvykti, for the treatment of multiple myeloma. The drug’s commercial performance has been formidable, generating $555 million in revenue during the fourth quarter of fiscal 2025 alone—a 64% surge compared to the same period the prior year. For the full fiscal year, total sales for the therapy reached $1.9 billion.

Notably, while Legend Biotech reported a net loss of $30.9 million for the final quarter, fiscal 2025 represented a significant operational turning point. The Carvykti program itself is now operating profitably. This improvement is supported by significant process optimizations; the success rate in the complex manufacturing of these cell therapies has climbed to 99%, creating a solid foundation for planned market expansion in the United States.

Should investors sell immediately? Or is it worth buying Legend Biotech Corp?

Market Sentiment and Analyst Outlook

Despite the operational progress, investor sentiment has remained cautious. The stock, trading at approximately €16.50, sits just below its 50-day moving average and has lost more than 53% of its value over the past twelve months. This market performance stands in contrast to the generally positive long-term view held by industry analysts, who cite the substantial patient potential for second-line treatments.

Recent analyst commentary includes:
– Morgan Stanley: Maintained an “Overweight” rating while adjusting its price target to $49.00 from $50.00.
– Jefferies: Forecasts Carvykti sales of $1.5 billion for 2026, with a projected increase to $2.4 billion by 2028.

The Path Forward

All strategic roads now lead to 2026. The central corporate objective is clear: to transition into sustained profitability by the end of that fiscal year. Investors will be closely monitoring the company’s ability to execute its scaling strategy efficiently while capitalizing on the global demand for its flagship therapy.